Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
St. Louis (April 9, 2019) - Intalere, the healthcare industry leader in delivering optimal cost, quality and clinical outcomes, today announced a new partnership with Ambry Genetics, a leading clinical genetic testing company. The collaboration will enable Intalere to offer its healthcare providers access to state-of-the-art clinical genetic testing and family history assessment, so they may better identify and manage patients with a high risk for cancer due to an inherited genetic mutation through the Ambry CARE (Comprehensive Assessment, Risk, and Education) Program.
“Numerous studies have shown that individuals at high risk for inherited cancer are not receiving necessary and timely clinical genetic testing,” said Tom Schoenherr, chief commercial officer of Ambry Genetics. “Ambry Genetics’ CARE program is a unique, end to end, customizable program that’s designed to help healthcare systems address this problem. Through CARE, we are able to assess populations of at-risk groups, provide risk values, genetic testing if needed, and then, through genetic counseling, educate patients on how their results may impact their current and future health.”
The benefits of Ambry Genetics’ CARE program are aligned with the triple AIM of healthcare, in that they are designed to improve the patient experience, enhance the health of populations, and reduce the per capita cost of healthcare by identifying cancers early and reducing the long-term costs of patient care.
Specifically, the CARE Program will benefit providers and patients by:
Schoenherr stressed that the CARE program is customizable. “We understand that health systems all have unique needs and requirements, so we provide a dedicated team of specialists who evaluate where and how to best implement these programs.”
Shon Wettstein, vice president of business development at Intalere, views the partnership with Ambry as an excellent fit. “We continually seek to partner with like-minded organizations that set the highest standards in their industry,” said Wettstein. “Ambry provides unmatched accuracy and specificity in their testing, offering patients and their families the most reliable and comprehensive information to proactively evaluate risk and identify any areas of concern.”
Intalere’s mission focuses on elevating the operational health of America’s healthcare providers by designing tailored, smart solutions that deliver optimal cost, quality and clinical outcomes. We strive to be the essential partner for operational excellence in healthcare through customized solutions that address customers’ individual needs. We assist our customers in managing their entire spend, providing innovative technologies, products and services, and leveraging the best practices of a provider-led model. As Intalere draws on the power of our owner Intermountain Healthcare’s nationally-recognized supply chain expertise and leadership in technology, process improvement, and evidence-based clinical and business best practices, we are uniquely positioned to be the innovation leader in the healthcare industry. Visit www.intalere.com to learn more.
Press Contact:
Evan Danis
Sr. Director, Corporate Communications
evan.danis@intalere.com
724-778-3423
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com